S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

OTCMKTS:NEPHNephros Stock Price, Forecast & News

$7.89
+0.38 (+5.06 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.56
Now: $7.89
$7.89
50-Day Range
$7.28
MA: $7.89
$8.56
52-Week Range
$4.42
Now: $7.89
$11.35
Volume7,339 shs
Average Volume14,139 shs
Market Capitalization$71.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NEPH
Previous SymbolNASDAQ:NEPH
CUSIPN/A
Phone201-343-5202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.69 million
Book Value$0.89 per share

Profitability

Net Income$-3,400,000.00

Miscellaneous

Employees18
Market Cap$71.33 million
Next Earnings DateN/A
OptionableNot Optionable
$7.89
+0.38 (+5.06 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEPH News and Ratings via Email

Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nephros (OTCMKTS:NEPH) Frequently Asked Questions

How has Nephros' stock been impacted by COVID-19 (Coronavirus)?

Nephros' stock was trading at $7.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NEPH stock has increased by 5.6% and is now trading at $7.89.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Nephros?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nephros
.

How were Nephros' earnings last quarter?

Nephros, Inc. (OTCMKTS:NEPH) released its earnings results on Wednesday, August, 5th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.04. Nephros had a negative net margin of 49.93% and a negative return on equity of 56.37%.
View Nephros' earnings history
.

What guidance has Nephros issued on next quarter's earnings?

Nephros updated its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.6-1.6 million, compared to the consensus revenue estimate of $2.24 million.

What price target have analysts set for NEPH?

2 analysts have issued 12-month price targets for Nephros' stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Nephros' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 102.8% from the stock's current price.
View analysts' price targets for Nephros
.

Has Nephros been receiving favorable news coverage?

Media coverage about NEPH stock has trended neutral this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nephros earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Nephros
.

Who are some of Nephros' key competitors?

What other stocks do shareholders of Nephros own?

Who are Nephros' key executives?

Nephros' management team includes the following people:
  • Mr. Daron G. Evans, Pres, CEO & Director (Age 45)
  • Mr. Andrew Astor, CFO & COO (Age 62)
  • Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.

What is Nephros' stock symbol?

Nephros trades on the OTCMKTS under the ticker symbol "NEPH."

Who are Nephros' major shareholders?

Nephros' stock is owned by many different institutional and retail investors. Top institutional investors include Cowen Prime Services LLC (2.80%). Company insiders that own Nephros stock include Andrew Astor, Daron Evans and Oliver J Spandow.
View institutional ownership trends for Nephros
.

Which institutional investors are buying Nephros stock?

NEPH stock was bought by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC. Company insiders that have bought Nephros stock in the last two years include Andrew Astor, Daron Evans, and Oliver J Spandow.
View insider buying and selling activity for Nephros
.

How do I buy shares of Nephros?

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nephros' stock price today?

One share of NEPH stock can currently be purchased for approximately $7.89.

How big of a company is Nephros?

Nephros has a market capitalization of $71.33 million and generates $5.69 million in revenue each year. The company earns $-3,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Nephros employs 18 workers across the globe.

What is Nephros' official website?

The official website for Nephros is www.nephros.com.

How can I contact Nephros?

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.